Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies

Tung Hoang; Seung-Kwon Myung; Thu Thi Pham

doi:10.4143/crt.2018.473

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(3); 2019 > Article

Original Article Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies: Tung Hoang, MPH¹, Seung-Kwon Myung, MD, PhD^2,3,4,, Thu Thi Pham, MPH¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(3):1022-1032.
DOI: https://doi.org/10.4143/crt.2018.473
Published online: October 17, 2018

¹Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea

²Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea

³Cancer Epidemiology Branch, National Cancer Center Research Institute, Goyang, Korea

⁴Department of Family Medicine and Center for Cancer Prevention and Detection, National Cancer Center Hospital, Goyang, Korea

Correspondence: Seung-Kwon Myung, MD, PhD Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-0479 Fax: 82-31-920-2606 E-mail: msk@ncc.re.kr

• Received: August 21, 2018 • Accepted: October 16, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

9,362 Views
185 Download
4 Web of Science
3 Crossref
3 Scopus

prev next

Full Article

This article has been retracted. See "RETRACTION: Dietary Intake of Omega-3 Fatty Acids and Endocrine-Related Gynecological Cancer: A Meta-Analysis of Observational Studies" in Volume 52 on page 334.

Abstract

Purpose
Previous observational epidemiological studies have reported inconsistent findings on the association between dietary intake of omega-3 fatty acids and endocrine-related gynecological cancer such as ovarian cancer and endometrial cancer. This study aimed to investigate this association using a meta-analysis of observational studies.
Materials and Methods
We searched PubMed, EMBASE, and Cochrane library by using key words related with the topic in April 2017. The pooled odd ratios (pORs), relative risks (pRRs), or hazard ratios (pHRs) with 95% confidence intervals (CIs) were calculated based on the random-effects model. Also, we performed subgroup meta-analysis by methodological quality, types of cancer, study design, and omega-3 fatty acids.
Results
A total of ten observational studies with six case-control and four cohort studies were included in the final meta-analysis. In the meta-analysis of all the studies, dietary intake of total omega-3 fatty acids was not significantly associated with the risk of endometrial and ovarian cancers (pOR/HR, 0.87; 95% CI, 0.73-1.04; I²=67.2%) (highest versus lowest intake). In the subgroup meta-analysis by type of study, there was no significant association between them in cohort studies (pHR, 1.03; 95% CI, 0.63-1.67, I²=81.9%), whereas its reduced risk was observed in case-control studies (pOR, 0.81; 95% CI, 0.67 to 0.98, I²=55.7%).
Conclusion
The current meta-analysis of observational studies suggests that there is no higher level of evidence to support the protective effect of dietary omega-3 fatty acids on endocrine-related gynecological cancer. Further prospective studies should be conducted to confirm the association.
Key words: Omega-3 fatty acids, Endometrial neoplasms, Ovarian neoplasms, Observational study, Meta-analysis

Introduction

Endometrial cancer and ovarian cancer are the most and second common type of gynecological malignancies, respectively, which are also called endocrine-related gynecological cancers [1]. There are several risk factors for endometrial cancer, which include body mass index, parity, age at menarche, oral contraceptives, diabetes, and smoking [2]. Age, contraceptive use, pregnancy, breastfeeding, and tubal ligation are known to be related to an increased risk of ovarian cancer [2].

In the meantime, it has been reported that biomarkers of inflammation such as C-reactive protein (CRP), interleukin-6, and tumor necrosis factor α are related to the increased risk of endometrial cancer [3,4] and ovarian cancer [5]. Previous meta-analyses of observational epidemiological studies have suggested that regular use of non-steroidal anti-inflammatory drug might be protective against these cancers [6,7]. Further, observational epidemiological studies [8,9] and randomized clinical trials [10-12] reported that omega-3 fatty acids such as α-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), which are polyunsaturated fatty acids abundant in vegetables, fruit, fatty fish, and supplements, might have anti-inflammatory actions. Regarding the potential effects of omega-3 fatty acids on the risk of endocrine-related gynecological cancers, several observational studies such as case-control studies and cohort studies [13-22] have reported inconsistent findings. However, no meta-analysis has been published on this topic.

The current study aimed to investigate the associations between dietary intake of omega-3 fatty acids and endocrine-related gynecological cancers by using a meta-analysis of observational epidemiological studies such as case-control studies and cohort studies and subgroup meta-analyses by various factors such as type of cancer, type of study design, type of omega-3 fatty acids, and study quality.

Materials and Methods

1. Literature search

Three different databases including MEDLINE (PubMed), EMBASE, and the Cochrane Library were systematically searched from their inception to April 2017 by using common keywords related to omega-3 fatty acids and endocrine-related gynecological cancers. The keywords for literature searching were listed as follows: “omega-3 fatty acid,” “fish oil,” “eicosapentaenoic acid,” “alpha-linolenic acid,” “docosahexaenoic acid,” “docosapentaenoic acid” for exposure factors; “endometrial cancer,” “uterine cancer,” and “ovarian cancer” for outcome factors. The bibliographies of relevant studies were also reviewed to identify additional publications. The languages of publication were not limited.

2. Study selection and eligibility criteria

The following are eligibility criteria for individual studies included in the meta-analysis: observational epidemiological studies such as case-control studies and prospective or retrospective cohort studies; studies that investigated the associations between dietary intake of omega-3 fatty acids and the risk of endocrine-related gynecological cancer. For studies using the same data, the more comprehensive study or the first published one was included in the final analysis. Based on the eligibility criteria, two investigators (Tung H and Thu Thi P) independently selected the potential studies.

3. Methodological quality assessment

We assessed the methodological quality of the included studies based on the Newcastle Ottawa Scale for observational studies [23]. The Newcastle Ottawa Scale consists of 3 subscales such as selection of studies, comparability, and exposure. Its star system ranges between 0 and 9. In our study, a study given more than a mean score in each study type was considered as having high quality.

4. Main and subgroup analyses

In the main analysis, we investigated the association between dietary intake of overall omega-3 fatty acids (highest versus lowest intake) and the risk of endocrine-related gynecological cancer. Subgroup meta-analyses were performed by type of study design (case-control study or cohort study), type of cancer (endometrial cancer or ovarian cancer), type of omega-3 fatty acids (ALA, EPA, DHA, or DPA), and methodological quality (high or low).

Bidoli et al. [14] and Tavani et al. [15] used the same dataset and transformed into the consumption of ALA and total omega-3 fatty acids intake in risk of ovarian cancer, respectively. To avoid overlaps, study of Bidoli et al. [14], which omega-3 fatty acids were performed much more specific, was only included in subgroup analysis. Besides, Tavani et al. [15] did not show the result for total omega-3 fatty acids and this study was also assessed for subgroup analysis by type of omega-3 fatty acids only.

5. Statistical analyses

We used adjusted odds ratios, relative risks, or hazard ratios (HRs) with 95% confidence intervals (CIs) from individual studies in order to calculate a pooled effect size. To measure heterogeneity across studies, we used Higgins I² [24], which is calculated as the following formula:

I²=100%×(Q–df)/Q

, where Q is Cochran’s heterogeneity statistic and df is the degrees of freedom. Negative values of I² are set at zero; I² ranges from 0% (no heterogeneity) to 100% (maximal heterogeneity). If I² value is greater than 50%, it represents the substantial heterogeneity [25]. Because individual studies were conducted in different populations, the random-effects model with the DerSimonian and Laird method was used to calculate the pooled effect size [26,27].

Publication bias was assessed by using the Begg’s funnel plot and Egger’s test [28]. If the funnel plot is asymmetric or the p-value for Egger’s test is lower than 0.05, there exists publication bias. The Stata SE ver. 14.0 software (StataCorp., College Station, TX) was used for all statistical analyses.

Results

1. Selection of relevant studies

Fig. 1 illustrates a flow diagram to identify relevant studies. A total of 3,531 articles were obtained from three databases. Among them, 375 duplicate articles were excluded. After reviewing a title and abstract of each article, we excluded 3,112 articles that did not satisfy selection criteria. Among them, 34 articles were excluded after reviewing the full texts of the remaining 44 articles. The reasons for exclusion were not relevant to study topic (n=9) and insufficient data for study outcome (n=25). A total of 10 studies with six case-control studies [14-17,19,22] and four cohort studies [13,18,20,21] were included in the final analysis.

2. General characteristics of studies

The general characteristics of the nine studies included in the final analysis are summarized in Table 1. The included studies were five case-control studies with a total of 12,523 participants consisting of 5,279 cases and 7,244 controls, which were published between 2002 and 2014 and four cohort studies with a total of 237,714 participants, which were published between 2002 and 2016. They were conducted in the United States (n=6), Italy (n=2), and Australia (n=1). The follow-up periods ranged between 1980 and 2013.

3. Methodological quality of studies

Table 2 shows the methodological quality of all the included studies based on the Newcastle Ottawa Scale. All the included studies were awarded 7 or 8 stars: three out of five case-controls studies and two out of four cohort studies were given 8. The mean score was 7.6 for case-controls studies and 7.5 for cohort studies.

4. Dietary intake of omega-3 fatty acids and risk of endocrine-related gynecological cancer

As shown in Fig. 2, compared to lowest intake of dietary omega-3 fatty acids, highest intake was not associated with the risk of endocrine-related gynecological cancer in the random-effects meta-analysis of case-controls studies (n=5) and cohort studies (n=3) (pooled odds ratio [pOR]/HR, 0.87; 95% CI, 0.73 to 1.04; I²=67.2%). In the meta-analysis by type of study, dietary intake of omega-3 fatty acids was not associated with risk of endocrine-related gynecological cancer in cohort studies (pHR, 1.03; 95% CI, 0.63 to 1.67; I²=81.9%; n=4), while a significantly decreased risk was found in case-control studies (pOR, 0.81; 95% CI, 0.67 to 0.98; I²=55.7%; n=5). No publication bias was observed in the main analysis: the Begg’s funnel plot was symmetrical, and the p for bias from the Egger’s test was 0.41 (Fig. 3).

Further, there was no significant association between dietary intake of omega-3 fatty acids and endocrine-related gynecological cancer in the subgroup meta-analyses by study quality (low vs. high), type of omega-3 fatty acids (ALA, EPA, DHA, and DPA), and type of cancer and type of study in each type of omega-3 fatty acids (Table 3, Fig. 4).

Discussion

1. Summary of findings

The current study found that there was no significant association between dietary intake of omega-3 fatty acids and the risk of endocrine-related gynecological cancer in the meta-analysis of cohort studies, while dietary intake of omega-3 fatty acids was associated with the decreased risk of endocrine-related gynecological cancer in case-control studies. These findings imply that there is no higher level of evidence to support the preventive effect of dietary intake of omega-3 fatty acids on endocrine-related gynecological cancer such as endometrial cancer and ovarian cancer.

2. Assessment of bias

The discrepancies in the effect of dietary intake of omega-3 fatty acids on the risk of these cancers between case-control studies and cohort studies might be associated with some important biases [29]. In general, case-control studies are more sensitive to selection bias and recall bias than prospective cohort studies [29]. Either a case group or control group might not represent the whole population because any group was a non-random sample from the population. This could lead to selection bias. Also, cancer patients might recall their dietary differently from controls: for example, they might answer that they had consumed less foods like fatty fish rich in omega-3 fatty acids. On the contrary, healthy people tend to report the healthy dietary habit, which may overestimate the true effect [30].

3. Comparison with previous studies

Our findings are consistent with those from the previous meta-analyses on the similar topic. Qiu et al. [31] reported that polyunsaturated fat intake was not associated with the risk of ovarian cancer in the meta-analysis of case-control studies and cohort studies. Also, Zhao et al. [32] found that there was no association between polyunsaturated fatty acid intake and the risk of endometrial cancer in the meta-analysis of case-control studies and cohort studies.

4. Possible mechanisms

There are several hypotheses regarding the potential protective effect of omega-3 fatty acids on endocrine-related gynecological cancer. A nested case-control study reported that increasing concentrations of CRP, which is a marker of chronic systemic inflammation, were associated the increased risk of ovarian cancer [5]. Another nested case-control study also suggested that CRP levels were positively associated with the risk of endometrial cancer [4]. It has been addressed that there are three overarching mechanisms regarding the pleiotropic anti-inflammatory and immunosuppressive properties of omega-3 fatty acids such as EPA and DHA: modulation of nuclear activation (e.g., nuclear factor-κB), suppression of arachidonic acid-cyclooxygenase-derived eicosanoids, and alteration of the plasma membrane micro-organization (lipid rafts) [33]. Regarding direct anti-carcinogenic mechanisms, previous preclinical models demonstrated that omega-3 fatty acids can reduce tumor cell proliferation, migration, and promote tumor cell apoptosis by inhibiting the mechanistic target of rapamycin complex 1 and 2 signaling, which is one of the major targets for the treatment of endometrial cancer [34]. Also, it has been reported that omega-3 fatty acids had anti-proliferative and anti-carcinogenic effects on epithelial ovarian cancer cell lines [35,36]. However, those anti-cancer effects of omega-3 effects were not observed in our meta-analysis of observational epidemiological studies.

5. Strengths and limitations

To the best of our knowledge, this is the first meta-analysis which reports the associations between dietary intake of omega-3 fatty acids and the risk of endocrine-related gynecological cancers. Our study has several limitations. Firstly, we included a relatively small number of individual studies with six case-control studies and four cohort studies. Thus, further large prospective cohorts studies are warranted to confirm our findings. Secondly, our findings should be limited to dietary intake of omega-3 fatty acids. We planned to evaluate the effects of omega-3 fatty acid supplements on the risk of endocrine-related gynecological cancer. However, when we searched three core databases (PubMed, EMBASE, and Cochrane Library), only VITAL study [18] reported the result which source of omega-3 fatty acids is from diet plus supplement. Thirdly, among studies included in the analyses, only Brasky’s study takes into consideration of dietary factors as adjustment variables. Lastly, our results were not able to be applied to Asians because published data originated from the Western countries, mainly the United States, and different methods of fish cooking between Western and Eastern countries and frequent intakes of raw fish in Far Eastern countries such as Japan and Korea as a source of dietary omega-3 fatty acids may affect the risk of endocrine-related gynecological cancer.

In conclusion, the current meta-analysis of observational studies suggests that there was no higher level of evidence to support the protective effect of dietary intake of omega-3 fatty acids on the risk of endocrine-related gynecological cancer such as endometrial cancer and ovarian cancer. Further larger prospective studies should be necessary to confirm our findings.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Flow diagram for selection of relevant studies.

Fig. 2.

Dietary omega-3 fatty acids intake and risk of endocrine-related gynecological cancer in a random-effects meta-analysis of observational studies by type of study (n=8) [15-22]. OR, odds ratio; HR, hazard ratio; CI, confidence interval.

Fig. 3.

Begg’s funnel plots and Egger’s test for publication bias. OR, odds ratio; HR, hazard ratio; SE, standard error.

Fig. 4.

Dietary omega-3 fatty acids intake and risk of endocrine-related gynecological cancer in a random-effects meta-analysis of observational studies by type of cancer (n=8) [15-22]. OR, odds ratio; HR, hazard ratio; CI, confidence interval.

Table 1.

General characteristics of 10 observational studies included in the analysis

Study	Source of participants (country)	Population (follow-up period)	Cancer type	Type of dietary omega-3 fatty acids	OR or RR or HR (95% CI)	Adjusted variable
Case-control study (n=6)
Bidoli et al. (2002) [14]	Multicentric case-control study (Italy)	1,031 Cases/2,411 controls (1991-1999)	Ovarian cancer	ALA	OR: 0.8 (0.6-1.0)	Age, study center, year of interview, education, parity, oral contraceptive use, and energy intake
Tavani et al. (2003) [15]				Total omega-3 fatty acids	OR: 0.6 (0.4-0.7)	Age, study center, education, body mass index (BMI), energy intake, and parity
Lucenteforte et al. (2008) [16]	Case-control study (Italy)	454 Cases/908 controls (1992-2006)	Endometrial cancer	ALA	OR: 1.0 (0.7-1.6)	Age and study center, adjusted for year of interview, education, physical activity, BMI, history of diabetes, age at menarche, age at menopause, parity, oral contraceptives use, hormone replacement therapy use, and total energy intake
Ibiebele et al. (2012) [17]	Australian ovarian cancer case-control study (Australia)	1,366 Cases/1,414 controls (2002-2005)	Ovarian cancer	ALA	OR: 1.19 (0.93-1.52)	Age, education, BMI, smoking status, oral contraceptive use, parity, menopausal status, hormonal replacement therapy, total fat intake, total energy, and total ω-6 fatty acid intake
				EPA	OR: 0.87 (0.70-1.09)
				DHA	OR: 0.92 (0.74-1.15)
				DPA	OR: 1.06 (0.85-1.33)
				Total omega-3 fatty acids	OR: 1.01 (0.80-1.28)
Arem et al. (2013) [22]	Population-based case-control study (United States)	556 Cases/533 controls (2004-2008)	Endometrial cancer	ALA	OR: 0.91 (0.63-1.32)	Energy consumption, age, BMI, number of live births, menopausal status, oral contraceptive use, hypertension, smoking status, and race/ethnicity
				EPA	OR: 0.57 (0.39-0.84)
				DHA	OR: 0.64 (0.44-0.94)
				Total omega-3 fatty acids	OR: 0.75 (0.52-1.09)
Merritt et al. (2014) [19]	New England case-control study (United States)	1,872 Cases/1,978 controls (1992-2008)	Ovarian cancer	Total omega-3 fatty acids	OR: 0.79 (0.66-0.96)	Age, study center, study phase, number of oral contraceptive use, family history of ovarian cancer, and history of tubal ligation
Cohort study (n=4)
Bertone et al. (2002) [13]	Nurses' Health Study cohort (United States)	80,258 Nurses (1980-1996)	Ovarian cancer	ALA	RR: 1.00 (0.72-1.39)	Age, parity, age at menarche, oral contraceptive use and duration, menopausal status/postmenopausal hormone use, tubal ligation, and smoking status
				EPA	RR: 0.97 (0.64-1.48)
				DHA	RR: 0.86 (0.55-1.33)
Brasky et al. (2014) [18]	VITamins and lifestyle cohort (United States)	22,494 Women (2000-2010)	Endometrial cancer	ALA	HR: 0.85 (0.56-1.29)	Age, race, education, BMI, pack-years of smoking, physical activity, alcohol consumption, age at menarche, age at ﬁrst birth, age at menopause, parity, years of combined hormone therapy, years of estrogen-only therapy, years of oral contraceptive use, oophoerectomy, family history of uterine cancer, family history of ovarian cancer, history of diabetes, and total energy
				EPA	HR: 1.73 (1.14-2.63)
				DHA	HR: 1.66 (1.09-2.55)
				EPA+DHA	HR: 1.79 (1.16-2.75)
Brasky et al. (2015) [20]	Women's Health Initiative observational study and clinical trial (United States)	87,360 Postmenopausal women (1993-2010)	Endometrial cancer	ALA EPA DHA DPA EPA+DPA+DHA	HR: 0.96 (0.79-1.18)	Intervention assignment, US region, race, education, BMI, smoking, alcohol, physical activity, age at menarche, age at ﬁrst birth, age at menopause, parity, duration of combined menopausal hormone therapy, duration of estrogen-alone hormone therapy, duration of oral contraceptive use, oophoerectomy status, family history of endometrial cancer, and history of diabetes
					HR: 0.81 (0.65-1.01)
					HR: 0.77 (0.63-0.95)
					HR: 0.85 (0.69-1.05)
					HR: 0.81 (0.66-1.00)
Brasky et al. (2016) [21]	Black Women's Health Study (United States)	47,602 African-American women (1995-2013)	Endometrial cancer	ALA	HR: 0.86 (0.56-1.33)	Age, time period, and total energy intake, U.S. region, education, BMI, physical activity, alcohol consumption, smoking, fruit consumption, vegetable consumption, age at menarche, age at menopause, parity, age at first birth, duration of combined hormone therapy, duration of estrogen-alone hormone therapy, duration of oral contraceptive use, and diabetes
				EPA	HR: 0.72 (0.47-1.10)
				DHA	HR: 0.84 (0.54-1.30)
				DPA	HR: 0.88 (0.57-1.36)
				EPA+DPA+DHA	HR: 0.79 (0.51-1.24)

OR, odds ratio; RR, relative risk; HR, hazard ratio; CI, confidence interval; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid.

Table 2.

Methodological quality of studies based on the Newcastle-Ottawa scale

Case-control study (n=6)	Selection				Comparability	Expose			Total
Case-control study (n=6)	Adequate definition of cases	Representati veness of cases	Selection of controls	Definition of controls	Comparability of cases and controls	Exposure ascertainment	Same ascertainment criteria for cases and controls	Non-response rate	Total
Bidoli et al. (2002) [14]	☆	☆	-	☆	☆☆	☆	☆	-	7
Tavani et al. (2003) [15]
Lucenteforte et al. (2008) [16]	☆	☆	-	☆	☆☆	☆	☆	-	7
Ibiebele et al. (2012) [17]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Arem et al. (2013) [22]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Merritt et al. (2014) [19]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Cohort study (n=4)	Selection				Comparability	Outcome			Total
Cohort study (n=4)	Representati veness of exposed cohort	Selection of non exposed cohort	Ascertainment of exposure	No present of outcome of interest at start of study	Comparability of cohorts	Assessment of outcome	Long follow-up enough for outcomes	Adequacy of follow-up of cohorts	Total
Bertone et al (2002) [13]	-	☆	☆	☆	☆☆	☆	☆	-	7
Brasky et al. (2014) [18]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Brasky et al. (2015) [20]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Brasky et al. (2016) [21]	-	☆	☆	☆	☆☆	☆	☆	-	7

Table 3.

Subgroup analysis by type of dietary omega-3 fatty acids and study quality

Factor	No. of studies	Pooled OR/RR/HR (95% CI)	I² (%)
Methodological quality
Low (score of 7 stars) [15,16,21]	3	0.76 (0.55-1.03)	52.7
High (score of 8 stars) [17-20,22]	5	0.93 (0.75-1.66)	72.1
Type of omega-3 fatty acids
EPA [13,17-22]	6	0.88 (0.69-1.12)	69.6
Endometrial cancer [18,20-22]	4	0.86 (0.58-1.30)	81.3
Ovarian cancer [13,17]	2	0.89 (0.73-1.08)	71.5
Case-control study [17,22]	2	0.73 (0.48-1.09)	71.4
Cohort study [13,18-20]	4	0.98 (0.69-1.39)	73.7
ALA [13,14,16-18,20-22]	8	0.96 (0.86-1.06)	39.8
Endometrial cancer [16,18,20-22]	5	0.93 (0.81-1.08)	0
Ovarian cancer [13,14,17]	3	0.99 (0.77-1.26)	58.6
Case-control study [14,16,22]	4	0.97 (0.79-1.18)	39.8
Cohort study [13,18,20,21]	4	0.94 (0.81-1.09)	0
DHA [13,17,18,20-22]	6	0.89 (0.72-1.10)	61.6
Endometrial cancer [18,20-22]	4	0.89 (0.63-1.28)	76.1
Ovarian cancer [13,17]	2	0.91 (0.75-1.11)	0
Case-control study [17,22]	2	0.79 (0.56-1.13)	61.9
Cohort study [13,18,20,21]	4	0.96 (0.69-1.35)	70.7
DPA [17,20,21]	3	0.94 (0.81-1.08)	3.5
Endometrial cancer [20,21]	2	0.86 (0.71-1.03)	0
Ovarian cancer [17]	1	1.06 (0.85-1.33)	NA
Case-control study [17]	1	1.06 (0.85-1.33)	NA
Cohort study [20,21]	2	0.86 (0.71-1.03)	0

OR, odds ratio; RR, relative risk; HR, hazard ratio; CI, confidence interval; EPA, eicosapentaenoic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; NA, not applicable.

REFERENCES

1. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21:1851–6. Article PubMed PMC PDF
2. Gibson DA, Simitsidellis I, Collins F, Saunders PT. Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer. 2014;21:T203–18. Article PubMed
3. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17:1007–19. Article PubMed PMC
4. Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev. 2011;20:971–7. Article PubMed PMC
5. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109:933–41. Article PubMed
6. Verdoodt F, Friis S, Dehlendorff C, Albieri V, Kjaer SK. Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: a systematic review and meta-analysis of observational studies. Gynecol Oncol. 2016;140:352–8. Article PubMed
7. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012;23:1839–52. Article PubMed PMC PDF
8. Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012;176:1002–13. Article PubMed PMC PDF
9. Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr. 2009;63:1154–6. Article PubMed PDF
10. Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol. 2009;64:321–7. Article PubMed
11. Malekshahi Moghadam A, Saedisomeolia A, Djalali M, Djazayery A, Pooya S, Sojoudi F. Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients. Singapore Med J. 2012;53:615–9. PubMed
12. Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis. 2009;204:476–82. Article PubMed
13. Bertone ER, Rosner BA, Hunter DJ, Stampfer MJ, Speizer FE, Colditz GA, et al. Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol. 2002;156:22–31. Article PubMed PDF
14. Bidoli E, La Vecchia C, Montella M, Maso LD, Conti E, Negri E, et al. Nutrient intake and ovarian cancer: an Italian case-control study. Cancer Causes Control. 2002;13:255–61. Article PubMed
15. Tavani A, Pelucchi C, Parpinel M, Negri E, Franceschi S, Levi F, et al. n-3 polyunsaturated fatty acid intake and cancer risk in Italy and Switzerland. Int J Cancer. 2003;105:113–6. Article PubMed
16. Lucenteforte E, Talamini R, Montella M, Dal Maso L, Tavani A, Deandrea S, et al. Macronutrients, fatty acids and cholesterol intake and endometrial cancer. Ann Oncol. 2008;19:168–72. Article PubMed PDF
17. Ibiebele TI, Nagle CM, Bain CJ, Webb PM. Intake of omega-3 and omega-6 fatty acids and risk of ovarian cancer. Cancer Causes Control. 2012;23:1775–83. Article PubMed PDF
18. Brasky TM, Neuhouser ML, Cohn DE, White E. Associations of long-chain omega-3 fatty acids and fish intake with endometrial cancer risk in the VITamins And Lifestyle cohort. Am J Clin Nutr. 2014;99:599–608. Article PubMed PMC PDF
19. Merritt MA, Cramer DW, Missmer SA, Vitonis AF, Titus LJ, Terry KL. Dietary fat intake and risk of epithelial ovarian cancer by tumour histology. Br J Cancer. 2014;110:1392–401. Article PubMed PMC PDF
20. Brasky TM, Rodabough RJ, Liu J, Kurta ML, Wise LA, Orchard TS, et al. Long-chain omega-3 fatty acid intake and endometrial cancer risk in the Women's Health Initiative. Am J Clin Nutr. 2015;101:824–34. Article PubMed PMC PDF
21. Brasky TM, Sponholtz TR, Palmer JR, Rosenberg L, Ruiz-Narvaez EA, Wise LA. Associations of dietary long-chain omega-3 polyunsaturated fatty acids and fish consumption with endometrial cancer risk in the Black women's health study. Am J Epidemiol. 2016;183:199–209. Article PubMed PMC PDF
22. Arem H, Neuhouser ML, Irwin ML, Cartmel B, Lu L, Risch H, et al. Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a population-based case-control study. Eur J Nutr. 2013;52:1251–60. Article PubMed PDF
23. Wells GA, Shea B, Connell DO, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa: Ottawa Hospital Research Institute; 2000. [cited 2017 Sep 18]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. Article PubMed
25. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions [Internet]. London: Cochrane Collaboration; 2011. [cited 2017 Sep 18]. Available from: http://www.handbook.cochrane.org/
26. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111. Article PubMed
27. Choi YJ, Myung SK, Lee JH. Light alcohol drinking and risk of cancer: a meta-analysis of cohort studies. Cancer Res Treat. 2018;50:474–87. Article PubMed PDF
28. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med. 2001;20:641–54. Article PubMed
29. Hammer GP, du Prel JB, Blettner M. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106:664–8. PubMed PMC
30. Giovannucci E, Stampfer MJ, Colditz GA, Manson JE, Rosner BA, Longnecker M, et al. A comparison of prospective and retrospective assessments of diet in the study of breast cancer. Am J Epidemiol. 1993;137:502–11. Article PubMed PDF
31. Qiu W, Lu H, Qi Y, Wang X. Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Oncotarget. 2016;7:37390–406. Article PubMed PMC
32. Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, et al. Dietary fat intake and endometrial cancer risk: a dose response meta-analysis. Medicine (Baltimore). 2016;95:e4121Article PubMed PMC
33. Chapkin RS, Kim W, Lupton JR, McMurray DN. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids. 2009;81:187–91. Article PubMed PMC
34. Zheng H, Tang H, Liu M, He M, Lai P, Dong H, et al. Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. Cancer Prev Res (Phila). 2014;7:824–34. Article PubMed
35. Sharma A, Belna J, Logan J, Espat J, Hurteau JA. The effects of omega-3 fatty acids on growth regulation of epithelial ovarian cancer cell lines. Gynecol Oncol. 2005;99:58–64. Article PubMed
36. Wan XH, Fu X, Ababaikeli G. Docosahexaenoic acid induces growth suppression on epithelial ovarian cancer cells more effectively than eicosapentaenoic acid. Nutr Cancer. 2016;68:320–7. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Association between dietary intake and risk of ovarian cancer: a systematic review and meta-analysis
Alireza Khodavandi, Fahimeh Alizadeh, Ahmad Faizal Abdull Razis
European Journal of Nutrition.2021; 60(4): 1707. CrossRef
RETRACTION: Dietary Intake of Omega-3 Fatty Acids and Endocrine-Related Gynecological Cancer: A Meta-Analysis of Observational Studies

Cancer Research and Treatment.2020; 52(1): 334. CrossRef
Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies
Keum Hwa Lee, Hyo Jin Seong, Gaeun Kim, Gwang Hun Jeong, Jong Yeob Kim, Hyunbong Park, Eunyoung Jung, Andreas Kronbichler, Michael Eisenhut, Brendon Stubbs, Marco Solmi, Ai Koyanagi, Sung Hwi Hong, Elena Dragioti, Leandro Fórnias Machado de Rezende, Louis
Advances in Nutrition.2020; 11(5): 1134. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies

Cancer Res Treat. 2019;51(3):1022-1032. Published online October 17, 2018

DOI: https://doi.org/10.4143/crt.2018.473

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies

Fig. 1. Flow diagram for selection of relevant studies.

Fig. 2. Dietary omega-3 fatty acids intake and risk of endocrine-related gynecological cancer in a random-effects meta-analysis of observational studies by type of study (n=8) [15-22]. OR, odds ratio; HR, hazard ratio; CI, confidence interval.

Fig. 3. Begg’s funnel plots and Egger’s test for publication bias. OR, odds ratio; HR, hazard ratio; SE, standard error.

Fig. 4. Dietary omega-3 fatty acids intake and risk of endocrine-related gynecological cancer in a random-effects meta-analysis of observational studies by type of cancer (n=8) [15-22]. OR, odds ratio; HR, hazard ratio; CI, confidence interval.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies

Study	Source of participants (country)	Population (follow-up period)	Cancer type	Type of dietary omega-3 fatty acids	OR or RR or HR (95% CI)	Adjusted variable
Case-control study (n=6)
Bidoli et al. (2002) [14]	Multicentric case-control study (Italy)	1,031 Cases/2,411 controls (1991-1999)	Ovarian cancer	ALA	OR: 0.8 (0.6-1.0)	Age, study center, year of interview, education, parity, oral contraceptive use, and energy intake
Tavani et al. (2003) [15]				Total omega-3 fatty acids	OR: 0.6 (0.4-0.7)	Age, study center, education, body mass index (BMI), energy intake, and parity
Lucenteforte et al. (2008) [16]	Case-control study (Italy)	454 Cases/908 controls (1992-2006)	Endometrial cancer	ALA	OR: 1.0 (0.7-1.6)	Age and study center, adjusted for year of interview, education, physical activity, BMI, history of diabetes, age at menarche, age at menopause, parity, oral contraceptives use, hormone replacement therapy use, and total energy intake
Ibiebele et al. (2012) [17]	Australian ovarian cancer case-control study (Australia)	1,366 Cases/1,414 controls (2002-2005)	Ovarian cancer	ALA	OR: 1.19 (0.93-1.52)	Age, education, BMI, smoking status, oral contraceptive use, parity, menopausal status, hormonal replacement therapy, total fat intake, total energy, and total ω-6 fatty acid intake
				EPA	OR: 0.87 (0.70-1.09)
				DHA	OR: 0.92 (0.74-1.15)
				DPA	OR: 1.06 (0.85-1.33)
				Total omega-3 fatty acids	OR: 1.01 (0.80-1.28)
Arem et al. (2013) [22]	Population-based case-control study (United States)	556 Cases/533 controls (2004-2008)	Endometrial cancer	ALA	OR: 0.91 (0.63-1.32)	Energy consumption, age, BMI, number of live births, menopausal status, oral contraceptive use, hypertension, smoking status, and race/ethnicity
				EPA	OR: 0.57 (0.39-0.84)
				DHA	OR: 0.64 (0.44-0.94)
				Total omega-3 fatty acids	OR: 0.75 (0.52-1.09)
Merritt et al. (2014) [19]	New England case-control study (United States)	1,872 Cases/1,978 controls (1992-2008)	Ovarian cancer	Total omega-3 fatty acids	OR: 0.79 (0.66-0.96)	Age, study center, study phase, number of oral contraceptive use, family history of ovarian cancer, and history of tubal ligation
Cohort study (n=4)
Bertone et al. (2002) [13]	Nurses' Health Study cohort (United States)	80,258 Nurses (1980-1996)	Ovarian cancer	ALA	RR: 1.00 (0.72-1.39)	Age, parity, age at menarche, oral contraceptive use and duration, menopausal status/postmenopausal hormone use, tubal ligation, and smoking status
				EPA	RR: 0.97 (0.64-1.48)
				DHA	RR: 0.86 (0.55-1.33)
Brasky et al. (2014) [18]	VITamins and lifestyle cohort (United States)	22,494 Women (2000-2010)	Endometrial cancer	ALA	HR: 0.85 (0.56-1.29)	Age, race, education, BMI, pack-years of smoking, physical activity, alcohol consumption, age at menarche, age at ﬁrst birth, age at menopause, parity, years of combined hormone therapy, years of estrogen-only therapy, years of oral contraceptive use, oophoerectomy, family history of uterine cancer, family history of ovarian cancer, history of diabetes, and total energy
				EPA	HR: 1.73 (1.14-2.63)
				DHA	HR: 1.66 (1.09-2.55)
				EPA+DHA	HR: 1.79 (1.16-2.75)
Brasky et al. (2015) [20]	Women's Health Initiative observational study and clinical trial (United States)	87,360 Postmenopausal women (1993-2010)	Endometrial cancer	ALA EPA DHA DPA EPA+DPA+DHA	HR: 0.96 (0.79-1.18)	Intervention assignment, US region, race, education, BMI, smoking, alcohol, physical activity, age at menarche, age at ﬁrst birth, age at menopause, parity, duration of combined menopausal hormone therapy, duration of estrogen-alone hormone therapy, duration of oral contraceptive use, oophoerectomy status, family history of endometrial cancer, and history of diabetes
					HR: 0.81 (0.65-1.01)
					HR: 0.77 (0.63-0.95)
					HR: 0.85 (0.69-1.05)
					HR: 0.81 (0.66-1.00)
Brasky et al. (2016) [21]	Black Women's Health Study (United States)	47,602 African-American women (1995-2013)	Endometrial cancer	ALA	HR: 0.86 (0.56-1.33)	Age, time period, and total energy intake, U.S. region, education, BMI, physical activity, alcohol consumption, smoking, fruit consumption, vegetable consumption, age at menarche, age at menopause, parity, age at first birth, duration of combined hormone therapy, duration of estrogen-alone hormone therapy, duration of oral contraceptive use, and diabetes
				EPA	HR: 0.72 (0.47-1.10)
				DHA	HR: 0.84 (0.54-1.30)
				DPA	HR: 0.88 (0.57-1.36)
				EPA+DPA+DHA	HR: 0.79 (0.51-1.24)

Case-control study (n=6)	Selection				Comparability	Expose			Total
Case-control study (n=6)	Adequate definition of cases	Representati veness of cases	Selection of controls	Definition of controls	Comparability of cases and controls	Exposure ascertainment	Same ascertainment criteria for cases and controls	Non-response rate	Total
Bidoli et al. (2002) [14]	☆	☆	-	☆	☆☆	☆	☆	-	7
Tavani et al. (2003) [15]
Lucenteforte et al. (2008) [16]	☆	☆	-	☆	☆☆	☆	☆	-	7
Ibiebele et al. (2012) [17]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Arem et al. (2013) [22]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Merritt et al. (2014) [19]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Cohort study (n=4)	Selection				Comparability	Outcome			Total
Cohort study (n=4)	Representati veness of exposed cohort	Selection of non exposed cohort	Ascertainment of exposure	No present of outcome of interest at start of study	Comparability of cohorts	Assessment of outcome	Long follow-up enough for outcomes	Adequacy of follow-up of cohorts	Total
Bertone et al (2002) [13]	-	☆	☆	☆	☆☆	☆	☆	-	7
Brasky et al. (2014) [18]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Brasky et al. (2015) [20]	☆	☆	☆	☆	☆☆	☆	☆	-	8
Brasky et al. (2016) [21]	-	☆	☆	☆	☆☆	☆	☆	-	7

Factor	No. of studies	Pooled OR/RR/HR (95% CI)	I² (%)
Methodological quality
Low (score of 7 stars) [15,16,21]	3	0.76 (0.55-1.03)	52.7
High (score of 8 stars) [17-20,22]	5	0.93 (0.75-1.66)	72.1
Type of omega-3 fatty acids
EPA [13,17-22]	6	0.88 (0.69-1.12)	69.6
Endometrial cancer [18,20-22]	4	0.86 (0.58-1.30)	81.3
Ovarian cancer [13,17]	2	0.89 (0.73-1.08)	71.5
Case-control study [17,22]	2	0.73 (0.48-1.09)	71.4
Cohort study [13,18-20]	4	0.98 (0.69-1.39)	73.7
ALA [13,14,16-18,20-22]	8	0.96 (0.86-1.06)	39.8
Endometrial cancer [16,18,20-22]	5	0.93 (0.81-1.08)	0
Ovarian cancer [13,14,17]	3	0.99 (0.77-1.26)	58.6
Case-control study [14,16,22]	4	0.97 (0.79-1.18)	39.8
Cohort study [13,18,20,21]	4	0.94 (0.81-1.09)	0
DHA [13,17,18,20-22]	6	0.89 (0.72-1.10)	61.6
Endometrial cancer [18,20-22]	4	0.89 (0.63-1.28)	76.1
Ovarian cancer [13,17]	2	0.91 (0.75-1.11)	0
Case-control study [17,22]	2	0.79 (0.56-1.13)	61.9
Cohort study [13,18,20,21]	4	0.96 (0.69-1.35)	70.7
DPA [17,20,21]	3	0.94 (0.81-1.08)	3.5
Endometrial cancer [20,21]	2	0.86 (0.71-1.03)	0
Ovarian cancer [17]	1	1.06 (0.85-1.33)	NA
Case-control study [17]	1	1.06 (0.85-1.33)	NA
Cohort study [20,21]	2	0.86 (0.71-1.03)	0

Table 1. General characteristics of 10 observational studies included in the analysis

OR, odds ratio; RR, relative risk; HR, hazard ratio; CI, confidence interval; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid.

Table 2. Methodological quality of studies based on the Newcastle-Ottawa scale

Table 3. Subgroup analysis by type of dietary omega-3 fatty acids and study quality